Showing 441-450 of 4075 results for "".
Assessing the Role of Phototherapy in Psoriasis
https://practicaldermatology.com/topics/psoriasis/assessing-the-role-of-phototherapy-in-psoriasis/19887/Despite therapeutic advancements, phototherapy remains a beneficial treatment for many psoriasis patients. Henry Lim, MD summarizes his presentation from San Diego Dermatology Symposium, emphasizing safety and COVID-19 protocols.Surgery Not Required?
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/surgery-not-required/19723/Patients increasingly want non-surgical options for skin tightening. Fortunately, a plethora of highly effective options exist, from ultrasound to radiofrequency, according to Mitchel Goldman, MD.AK Pearls: Managing Treatment Reactions
https://practicaldermatology.com/topics/skin-cancer-photoprotection/ak-pearls-managing-treatment-reactions/18741/Dr. Bhatia shares pearls for managing side effects and reactions to actinic keratosis treatment drugs. There are many adjunctive therapies to counter these reactions from emollients to barrier repair cream to time and some TLC for patients.Drug Prices Soar, Amgen Files BLA for Biosimilar to Humira
https://practicaldermatology.com/topics/practice-management/dermwiretv-drug-prices-soar-amgen-files-bla-for-biosimilar-to-humira/18672/In this edition, Amgen Submits ABP 501—first Adalimumab biosimilar; prices for dermatology drugs jump and a survey explores patient knowledge of antibiotic resistance. Also, Almirall acquires Veltin from Sitefel/GSK.Psoriasis Pipeline Update: JNJ-2113, A Novel Oral IL-23 Receptor Antagonist Peptide, Shows Promise in a Phase 2b Study
https://practicaldermatology.com/topics/psoriasis/psoriasis-pipeline-update-jnj-2113-a-novel-oral-il-23-receptor-antagonist-peptide-shows-promise-in-a-phase-2b-study/20207/Laura Korb Ferris, MD, PhD, discusses the topline results from a Phase 2b trial of JNJ-2113, a novel oral IL-23 receptor antagonist peptide that’s being developed for moderate-to-severe plaque psoriasis.Welcome to the Dermatology Hub: Neuroimmune Network
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/tbd/39772/Practical Dermatology chief medical editor Neal Bhatia, MD, FAAD, explains what clinicians can expect from the Dermatology Hub: Neuroimmune Network, a unique editorial platform that will be updated monthly with exciting new content.Shifting Paradigms on Lentigo Maligna
https://practicaldermatology.com/conferences/maui-derm-2024/shifting-paradigms-on-lentigo-maligna/20255/According to Ashfaq Marghoob, MD, current research supports individualizing treatment of lentigo maligna (LM) based on what is the best therapeutic option, from active surveillance to surgery to radiation to imiquimod.SCALE 2024: Dr. Michael Gold Recaps the Show and Previews 2025
https://practicaldermatology.com/conferences/scale-2024/scale-2024-dr-michael-gold-recaps-show-and-previews-2025/26751/Michael Gold, MD, FAAD, Course Co-Director for Music City SCALE, discusses the growth of the event over the years, highlights from 2024, and what to expect next year.Addressing Skin Changes During Menopause: An Update
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/addressing-skin-changes-during-menopause-an-update/20220/New York City-based dermatologist Ellen Gendler, MD, shares pearls from her recent talk at the 2023 annual meeting of the Menopause Society including the current thinking on how to address the effects of diminished estrogen on skin.SDPA: Dr. Audrey Rutherford Shares How Vulvovaginal Dermatology Became Her Specialty
https://practicaldermatology.com/conferences/sdpa-2024/sdpa-dr-audrey-rutherford-shares-how-vulvovaginal-dermatology-became-her-specialty/29511/At the SDPA 22nd Annual Fall Dermatology Conference, Practical Dermatology caught up with Audrey Rutherford, MD. Dr. Rutherford shares how she got started in vulvovaginal dermatology and key takeaways from her lecture.